Teva Pharma Industries Ltd ADR (TEVA)vsViatris Inc (VTRS)
TEVA
Teva Pharma Industries Ltd ADR
$35.73
-0.78%
HEALTHCARE · Cap: $41.93B
VTRS
Viatris Inc
$17.17
-1.27%
HEALTHCARE · Cap: $20.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 19% more annual revenue ($17.35B vs $14.56B). TEVA leads profitability with a 9.0% profit margin vs -2.0%. VTRS appears more attractively valued with a PEG of 0.15. TEVA earns a higher WallStSmart Score of 62/100 (C+).
TEVA
Buy62
out of 100
Grade: C+
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.3%
Fair Value
$63.92
Current Price
$35.73
$28.19 discount
Margin of Safety
+33.6%
Fair Value
$24.30
Current Price
$17.17
$7.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 72.2% YoY
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, Return on Equity.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.15 suggests the stock is reasonably priced for its growth.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
TEVA profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.87 — expect wider price swings.
VTRS is growing revenue faster at 8.1% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (62/100 vs 48/100). VTRS offers better value entry with a 33.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?